Seed · Biotech · Tallinn, Estonia · Founded 1998 · 1–10 employees
GeneCode is a preclinical-stage biopharmaceutical development company focused on creating disease-modifying small-molecule therapeutics to combat neurodegenerative diseases. Utilizing its proprietary GDNF Mimetics platform, the company designs small molecules that can cross the blood-brain barrier to treat Parkinson's disease, Amyotrophic Lateral Sclerosis, and Inflammatory Bowel Disease. In December 2024, the company secured a €1.5 million R&D grant from the Estonian Business and Innovation Agency to advance its research. This funding follows a substantial €16 million EIC Accelerator package secured in July 2023, consisting of a €1.7 million grant and a €14.3 million equity investment commitment.
No open roles listed right now.